粉样纤维结构将CHCHD10和CHCHD2与神经退行联系起来
Guohua Lv1, Nicole M Sayles2, Yun Huang3,4
1Department of Biochemistry, Weill Cornell Medicine, 1300 York Avenue, New York, NY, USA.
Nature communications
|August 2, 2025
概括
线粒体蛋白CHCHD10和CHCHD2形成与FTD,ALS和PD等神经退行性疾病相关的粉样纤维. 这些蛋白质的突变改变了纤维细胞结构,这表明它们在疾病发展中的作用.
科学领域:
- 生物化学 生化学
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
背景情况:
- 线粒体蛋白CHCHD10和CHCHD2与罕见的可遗传形式的前性痴呆 (FTD),肌缩性侧面硬化症 (ALS) 和帕金森病 (PD) 有关.
- 已知这些蛋白质会聚集在受影响的组织中,这表明它们可能在疾病发病过程中发挥作用.
研究的目的:
- 为了研究CHCHD10和CHCHD2.2的纤维化倾向.
- 为了确定CHCHD10和CHCHD2粉样纤维素形成的结构基础.
- 了解疾病相关突变对纤维细胞结构和形成的影响.
主要方法:
- 电子显微镜 (cryo-EM) 用于确定纤维结构.
- 对蛋白质聚合和纤维细胞形成的生物化学分析.
主要成果:
- 无论是CHCHD10还是CHCHD2,都会形成粉样纤维.
- 这些纤维的有序核心来自CHCHD10和CHCHD2.2之间的保存区域.
- 疾病相关的突变 (p.S59L在CHCHD10,p.T61I在CHCHD2) 在有序核心中破坏野生型结构并促进明显的纤维状形状.
结论:
- CHCHD10和CHCHD2粉样纤维在结构上与神经退行有关.
- 在CHCHD10和CHCHD2中发生的突变改变了纤维细胞的形成,为它们在FTD,ALS和PD中的作用提供了分子基础.
- 野生型CHCHD10和CHCHD2纤维细胞的形成也可能导致神经退行性疾病的病因.
相关概念视频
03:03Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669